A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前研究表明液中蛋白含量越高，其发展成心脏病可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物巨大潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白领域内,疾病蛋白在医和生物药方面具有发子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前研究表明人血液中含量越高，其发展成心脏病可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能组领域内,疾病组学在医学和生物药方面具有发现新分子药靶、生物标志物潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其,能蛋白质组领域内,疾病蛋白质组学医学和生物药方面具有发现新分子药靶、生物标志物的巨大的。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组,疾病蛋白质组学在医学和生药方面具有发现新分子药靶、生的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊，发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊，发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质内,疾病蛋白质学在医学和生药方面具有发现新分子药靶、生的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前研究表明人血液中蛋白含量越高，其发展成心脏病可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白域内,疾病蛋白学在医学和生药方面具有发现新分子药靶、生标巨大潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化一项实验室依据。